

拥有 40  
年历史的制药企业





## 40

该公司于 1982 年在印度旁遮普省成立，目的是生产活性药物成分。

该公司是一家活性药物成分 (API)

制造公司，为制药行业的几家领先公司生产原材料，这些公司使用这些产品来制造药物。

他们为辉瑞、雅培、Cipla、Glenmark、Macleods、Aristo 等公司提供产品。

该公司提供的产品范围从抗生素、维生素、抗凝血剂到眼科产品。

印度和海外的监管机构也对业务进行了多个组织的审核，例如 ISO、ZED 和 GMP。

企业正在研究重组蛋白的专利技术，该技术可用于新型靶向治疗，并确保无副作用。

目前，运营重点是高端新型分子。

研究

公司目前正在进行干细胞再生疗法的实验研究，这也有望成为未来没有任何副作用的药物。

生物技术

该公司在靶向人类治疗蛋白领域从事重要的生物技术研究活动。

其目前的研究工作重点是创造一种新药，在治疗哮喘和过敏患者的同时，还可以治疗肥大细胞增多症和嗜碱性白血病。

团队

团队由100名开明人士组成，包括化学家、药剂师、生物技术专家、质量控制人员、研发专家、仓储人员。

65% 印度/35% 世界其他地区/欧洲

25 种 OEM 产品/医药活性成分原材料

： 抗生素

： ISO9001、欧盟标准（无 FDA）

： 20%+/年

100 多名员工

### TARGET PRICE

\$40,000,000

### GROSS REVENUE

\$25,000,000

### EBITDA

\$3,000,000

### BUSINESS TYPE

制造业

### ESTABLISHED

1989

### SUPPORT & TRAINING

12个月

### REASON FOR SELLING

退休

### COUNTRY

印度

### BUSINESS ID

L#20210013

化学工程师背景

收入 2500 万美元 / EBITDA 300 万美元

顾客：



**Abbott**



**glenmark**  
*A new way for a new world*

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

[www.mergerscorp.com](http://www.mergerscorp.com)



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)